Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
For orders under $99 AUD, delivery is available from $9.90 AUD
These events were generally mild to moderate in severity and included: Nausea often accompanying changes in bowel habits, particularly after dose escalation Diarrhoea loose or watery stools, sometimes with urgency Vomiting less common but reported, especially at higher doses Constipation occurring in some individuals, reflecting the variable effect on gut motility Abdominal discomfort or bloating a sensation of fullness or cramping Flatulence increased wind, which can accompany altered digestion Gastrointestinal adverse events were the most common reason for discontinuation in the Phase 2 trial, occurring in approximately 510% of participants depending on dose group
Will it get worse over time
Delafloxacin, a non-zwitterionic fluoroquinolone in phase III of clinical development: Evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy
US$ 23.24
US$ 20.95
US$ 22.28
US$ 24.22
